**Name of journal: World Journal of Clinical Cases**

**ESPS Manuscript NO: 12831**

**Columns: MİNİREVİEWS**

**Role of immunotherapy in the treatment of allergic asthma**

Yukselen A *et al*. Immunotherapy and allergic asthma

Ayfer Yukselen, Seval Guneser Kendirli

**Ayfer Yukselen,** Clinic of Pediatric Allergy and Immunology, Gaziantep Children Hospital, Sehitkamil, 27310 Gaziantep, Turkey

**Seval Guneser Kendirli,** Division of Pediatric Allergy and Immunology, Cukurova University Faculty of Medicine, Balcali, Adana 01150, Turkey

**Author contributions:** Yukselen A wrote the paper; and Kendirli SV reviewed the paper.

**Correspondence to**: **Ayfer Yukselen, MD, Associate Professor** of Pediatrics, Clinic of Pediatric Allergy and Immunology, Gaziantep Children Hospital, Sehitkamil, 27560 Gaziantep, Turkey. [ayfyukselen@gmail.com](mailto:ayfyukselen@gmail.com)

**Telephone:** +90-342-2200072

**Received:** July 27, 2014 **Revised:** August 27, 2014

**Accepted:** October 14, 2014

**Published online:**

**Abstract**

Allergen-specific immunotherapy (SIT) induces clinical and immunological tolerance as defined by persistence of clinical benefit and associated long-term immunological parameters after cessation of treatment. Although the efficacy of SIT has been shown in terms of reducing symptoms, medication consumption and ameliorating quality of life in both allergic rhinitis and asthma, there has long been some controversies about effectiveness of SIT in the treatment of allergic asthma. The type of allergen, the dose and protocol of immunotherapy, patient selection criteria, the severity and control of asthma, all are significant contributors to the power of efficacy in allergic asthma. The initiation of SIT in allergic asthma should be considered in case of coexisting of other allergic diseases such as allergic rhinitis, unacceptable adverse effects of medications, patient’s preference to avoid long-term pharmacotherapy. Steroid sparing effect of SIT in allergic asthma is also an important benefit particularly in patients who have to use these drugs in high doses for a long-time. Symptomatic asthma is a risk factor for systemic reactions and asthma should be controlled at the time of administraion of SIT. Both subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) have been found to be effective in patients with allergic asthma. Although the safety profile of SLIT seems to be better than SCIT, the results of some studies and meta-analyses suggest that the efficacy of SCIT may appear better and earlier than SLIT in children with allergic asthma.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words**: Asthma; Efficacy; Safety; Subcutaneous immunotherapy; Sublingual immunotherapy

**Core tip:** Allergen specific immuntherapy is the only therapeutic approach that can change the immunologic response to allergens and thus can alter the natural evolution of allergic diseases. Both subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) have been demonstrated to be beneficial in reducing of symptoms and drug intake,improving quality of life and preventing patients from possible side effects of high doses of steroids. This review examines the clinical effectiveness and safety of both SCIT and SLIT in patients with asthma by discussing recent studies.

Yukselen A, Kendirli SG. Role of immunotherapy in the treatment of allergic asthma. *World J Clin Cases* 2014,In press

**INTRODUCTİON**

Asthma is one of the most prevalent chronic conditions affecting roughly 300 million people in the world. It is supposed that asthma will affect an additional 100 million people by 2025[1].

According to data of health statistics in United States, current asthma prevalence is 9.3% and 8%, in children and adults, respectively[2]. This incrementin the prevalence of asthma has been accompanied by an incrementin other allergic disorders like rhinitis and eczema.

Asthma is characterized by chronic inflammation, which result in recurrent attacks of cough, wheezing, sometimes chest tightness and variable airflow obstruction. As time progresses, thisairflow obstruction may becomeirreversibledue to airway remodelling.Since many years, asthma has been supposed as mainly a Th2 cell-mediated disorder[3,4]. Nevertheless, in recent years, it is also discovered that many other cell types such as Treg, Th1 and Th17 are also involved in pathological process of asthma[3,4].

Drugs, such as inhaled corticosteroids, long-acting beta agonists and montelukast can effectively control asthma symptoms and attacks. However, it is known that, pharmacotherapy can not affect the underlying immune response; when these medications are stopped the symptoms may reccur.

Specific allergen immunotherapy (SIT) is a unique therapy which capable to change the natural evolution of allergic diseases[5]. With this treatment mode, allergens are given to patients in repeated and increasing doses to provide immune tolerance[6].

The effectivenessof both subcutaneous (SCIT) and sublingual (SLIT) immunotherapy is documented for both perennial and seasonal allergic respiratory disease by systematic reviews and meta-analyses[6-11].For almost 100 years now,subcutaneous route has been used totreat allergic diseases;however, there are many studies to confirm the administration of SLIT because of discomfort of repeated injections and higher risk of adverse reactions.

In most published studies, effectiveness of SIT has been assessed primarily in patients with allergic rhinitis,and the results concerning asthma mostly were given as secondary outcome. Thus, there are a few studies which were organised to evaluate the efficacy of SIT specifically in asthma alone.

In this paper wewill review primarily the clinical efficacy and safety of both SCIT and SLIT in patients with allergic asthma in the light of the literature.

**CLİNİCAL EFFİCACY OF SCIT İN ASTHMA**

The first of the studies which evaluate the efficacy of SCIT in asthmatic patients published by Abramson in 1995[12].

In the meta-analysis carried out by Ross *et al*[13],24 prospective, randomized,studies involving 962 asthmatic patientswere evaluated. They reported significant amelioration in symptoms and drug intake related with asthma as well as in pulmonary function in the SCIT group in comparison to the placebo. It was deduced that immunotherapy was beneficial in 17 (71%) studies, inefficacious in 4 (17%) studies,and equivocal in 3 (12%) studies. Similar to the previousmeta-analyses, the authors concluded that SIT is effective in patients suffering from allergic asthma.

In a study of Basomba *et al*[14], 55 mild and moderate asthmatic patients (aged 14-50 years) allergic to house dust mites (HDM) were treated with *D pteronyssinus* extract encapsulated in liposomes, in a double-blind placebo-controlled manner. At the end of one year, 45.8% of the patients treated with SCIT decreased symptom and medication scores by at the minimum 60%. There were also notable improvements in results of skin test and allergen-specific bronchial challenge.

In another study, fifteen children aged 6-14 years with asthma due tue HDM were treated with SCIT for three years; the results were remarkable reduction in the number of asthma excerbations and marked decrease in drug intake[15].Additionally, significant improvement in lung functions and non-specific bronchial hyperreactivity (BHR) wereobserved.

Garcia-Robaina *et al*[16] administered SIT with HDM in 64 adult asthmatic patients and they observed notable amelioration in the active group over placebo in terms of symptom (53.8 %) and medication scores (58%) in addition to improvement in allergen-specific BHR.

Roberts *et al*[17]studied the efficacy of grass pollen SIT in 35 asthmatic patients (aged 3-16 years) over 2 pollen season in a double–blind manner. They found that SIT provided significant decreases in asthma symptom and medication scores, marked improvements in cutaneous (*P* = 0.002), conjunctival (*P* = 0.02), and bronchial (*P* = 0.01) reactivity to allergen.

In the study of Zielen *et al*[18], 65 mite allergic children aged 6-17 years were treated with subcutaneous allergoid immunotherapy plus fluticasone propionate (FP) or FP therapy alone for 2 years. Before starting SIT, asthma control was achieved using inhaled corticosteroids for 5 mo follow-up. Children treated with SCIT plus FP were able to markedly decrease the FP dose, in comparison to the control group given only FP. After 2 years of treatment, the mean daily FP dose decreased from 330.3 μg to 151.5 μg in the immunotherapy group while there was no significant reduction in the control group.

In a recent Cochrane review of SCIT, 88 studies on 3459 subjects with asthma were evaluated; there were 42 trials for dust mites, 27 for pollen, 10 for animal dander, two for molds, two for latex, and six for multiple allergens[19]. It was reported that SCIT improved asthma symptoms, reduced medication use, and diminished BHR. The conclusion of this review was summarized as:‘it would require treating three subjects to prevent an exacerbation for one individual, four subjects to improve medication use in one, and four subjects to avoid nonspecific or allergen-specific BHR in one patient, respectively.’Additionally, mite and pollen immunotherapy were found more effective on symptom scores.

There are several studies of SCIT(particularly with mites[20-21] or mixed-allergen up to seven aeroallergens[22]) which demonstratedthe improvement in asthma symptom and medication scores to a lesser degree than the other published studies. Nevertheless, significant steroid- sparing effect of immunotherapy was shown in moderate persistent asthmatics included in those studies.Thus, it should be kept in mind that the maintenance of asthma control is very important before and during the study in order to obtain optimal benefit of the immunotherapy.

**CLİNİCAL EFFİCACY OF SLIT İN ASTHMA**

World Allergy Organization Position Paper on Sublingual Immunotherapydeclared that SLIT is effective in the treatment of allergic rhinitis in adults and in allergic rhinitis and asthma in children[23].However, it is also stated the presence of some important points about current status of SLIT effectiveness. It is known that there are significant heterogenity between studies included in SLIT meta-analyses, and this may bring significant limitation on the conclusion of them.

The first meta-analysis on SLIT in asthma was conducted by Olaguibel *et al*[24] and comprised of seven studies in 256 children aged up to 14 years. This study showed marked improvements in symptom scores (SMD: -1.42) and medication requirement scores (SMD: -1.01) related with asthma.

In 2006, a meta-analysis about SLIT in asthma included 25 trials and involved 1706 adults and children[25]. This meta-analysis reported a significant efficacy of SLIT for symptoms and medication use in seven studies, and improvement in pulmonary function in four studies. But, when asthma symptoms and drug intake were analysed as ongoing parameters, the reductions were not significant.

Penagos *et al*[26]evaluated the efficacy of SLIT by conducting a meta-analysis which included nine studies on 441 asthmatic children. Six of these studies were with mites and three of them with pollen. The authors found significant decrease in symptom and medication scores with SLIT in comparison to placebo.

In 2009, Compalati *et al*[10] published a meta-analysis which evaluate nine studies in 452 patients treated with SLIT in HDM-allergic asthma. They reported marked improvement in symptomand medication scoresrelated with asthma. As in SCIT, the steroid sparing effect of SLIT was also demonstrated in some recent published studies[27,28].

In the study of Marogna *et al*[28], 84 asthmatics were randomized to four treatment arms for three years: first group received budesonide 800 μg/d; second group received budesonide 1600 μg/d; third group treated with budesonide 400 μg/d plus montelukast 10 μg/d; and fourth group was given budesonide 400 μg/d plus allergoid of betulaceae pre-coseasonally.Low-dose inhaled corticosteroids plus SLIT provided a marked advantageover the other options on symptoms plus medications decrease, FEV1 increase, rescue medications usage, and was comparable to low-dose inhaled corticosteroids plus montelukast on MEF25 and BHR.

Similarly, in a study involving 602 mite allergic asthmatic patients, it was shown that daily treatment with SLIT tablet reduced inhaled budesonide more than 80 ug/day in comparison to placebo after 1 year[27].

**HEAD-TO HEAD STUDİES**

There are 4 randomized controlled trials with 171 participants which compare SCIT with SLIT directly in asthmatic patients. All these studies enrolled mite allergic patients with rhinitis and/or asthma. Efficacy of SIT was investigated by evaluating the clinical outcomes for both rhinitis and asthma.

In the first of these studies, Mungan *et al*[29], randomized 36 adults with HDM-allergic rhinitis and asthma to receive SCIT, SLIT or placebo. They found that one-year of SCIT improved symptom scores of both rhinitis and asthma while SLIT had benefit only on symptoms of rhinitis. However,  medication scores of both rhinitis and asthma decreased significantly in both actively treated groups. After 1 year of immunotherapy, it was also shown marked rises in specific IgG4 concentrations in comparison to the baseline both in SLIT and SCIT groups.

Eifan *et al*[30] evaluatedthe effectiveness of SCIT and SLIT in children with asthma/rhinitis sensitized to mites. Forty eight children were randomized to treat either SCIT, SLIT or pharmacotherapy. This study demonstrated that both SLIT and SCIT have a significant positive effect on symptoms and medication usagerelated with both rhinitis and asthma in comparison to the pharmacotherapy group. Additionally, after 1 year of treatment, Der p 1-driven IL-10 signiﬁcantly increased in SLIT in comparison to pharmacotherapy, whereas Bet v 1-driven TGF-b increased signiﬁcantly in SLIT only.

In the study of Keles *et al*[31], 48 patients (aged 5-10 years) with mild persistent asthma and rhinitis mono-sensitized to mites were randomized to three treatment arms: they received either SLIT (*n* = 16), SCIT (*n* = 16) or pharmacotherapy alone (*n* = 16). After 12-month of treatment, total asthma symptom scores (*P* = 0.02) and visual analog scores (*P* = 0.02) decreased markedly in SLIT when compared with the pharmacotherapy group. Similarly, SCIT also reduced both total asthma symptomscores (*P* = 0.04) and visual analog scores (*P* = 0.001) when compared with the pharmacotharapy group. The percentage of improvement was 100 % and 93 % in SLIT and SCIT group respectively, in comparison to the pharmacotherapy group. A marked increment was seen in the levels of regulatory and Th1 cytokines both in the SCIT and SLIT groups. Antigen-specific IgG4 levels increased in the SCIT and SCIT plus SLIT groups but not in the SLIT group.

In a recent randomized, placebo-controlled and double- dummy study we investigated the effectiveness of SCIT and SLIT in HDM- allergic children with asthma and/or rhinitis[32]. We showed that one-year SCIT had significant effect on symptom and medication scores related with both rhinitis and asthma. An important observation in this study was the better effect of only SCIT over placebo on reduction of rhinitis and asthma symptoms at the end of one-year-treatment. Bronchial challenge doses and sputum eosinophil increments after bronchial challenge decreased only with SCIT. There was no change in terms of IFN-γ levels in both immunoptherapy groups. Serum sIgG4 levels increased significantly only in the SCIT group.This study then carried on one subsequent year in an open scheme and the placebo group was randomized to treat SCIT or SLIT. Thus, all patients received active treatment with SCIT or SLIT during one subsequent year[33]. We observed that the effect of SLIT on asthma symptoms and drug intake was less eminent than SCIT in the first year; however this effect was more pronounced in the second year of SLIT. With this study, we concluded that both clinical and immunologic improvement starts earlier with SCIT in comparison to the SLIT in mite-allergic children with rhinitis and asthma.

The summary of these 4 head-to-head studies was shown in Table 1. Recently, a systematic review of studies with head-to-head comparison of SCIT and SLIT in the treatment of allergic rhinoconjunctivitis and asthma was published[34]. Four trials conducted in patients with rhinitis and/or asthma[29-32]. This review demonstrated that low-grade evidence confirms more efficacy of SCIT than SLIT regarding reduction of asthma symptoms and combined measure of rhinitis symptoms and drug intake; moderate-grade evidence confirms more efficacy of SCIT than SLIT for nasal and/or eye symptom reduction. It was deduced that low-grade evidence confirmsthat SCIT is more beneficial than SLIT for reduction in asthma symptoms and moderate-grade evidence for reduction of allergic rhinoconjunctivitis. Further studies are required to support this results for clinical decision making.

**SAFETY OF SCIT AND SLIT**

It is known that SCIT has a risk for both local and systemic adverse reactions but, in most of the cases, symptoms are reversible if they are diagnosed early and treated rapidly. All allergen preparations (standardized extracts[35], allergoids[36] or recombinant allergens[37]can cause these side effects.

The incidence of systemic reactions of SCIT varies between 0.06% and 1.01% in those receiving injections[38].

A recent multicenter study suggested that systemic reactions were slightly more frequent in rhinitis with asthma than rhinitis patients alone[39]. Some reports have been suggested that asthma may be a risk factor for severe systemic reactions due to SCIT, notably in patients with uncontrolled asthma. Conversely, another retrospective study reported no significant association between systemic reactions and the presence of asthma[40]. As noted by official documents, the patients’s general condition and pulmonary functions should be assesed before injection in order to reduce the risk of anapylaxis[41].

The safety of SLIT seems better than subcutaneous therapy regarding severe systemic reactions. Local side effects (oral itching or mild swelling) may be encountered in three-fourths of patients especially in the early phase of SLIT.

In the study of Dahl *et al*[42] the safety of SLIT investigated specifically in grass pollen allergic patients with asthma. They evaluated side effects which may be related with asthma e.g cough, wheezing, and they found no difference in the number of such effects between active and placebo group. Additionally, no asthma exacerbation related with SLIT was reported in this study.

There are also some recommendations about administering of SLIT in patients with systemic reactions after subcutaneous immunotherapy[43]. Nonetheless, some patients suffering from these adverse reactions with subcutaneous route may entertain the same risk for sublingual route of immunotherapy[44].Thus, our recommendation is that immunotherapy should be customized to each patient on the basis of the degree of sensitization, concomitant allergies, exposures and patient’s preference.

**PREVENTİVE CAPACİTY OF SIT**

SIT builts up clinical and immunological tolerance as shown by persistence of improvement both in clinical and immunologic parameters after the cessation of treatment. Additional long-term benefits of SIT include prevention of new sensitizations and progression from rhinitis to asthma.

There are some studies which demonstrated the preventive effect of SIT in pediatric population. At the 10-year follow-up (7 years after cessation ofimmunotherapy) the children in the immunotherapy group had significantly less asthma in comparison to the control group: 16/64 (25%) with asthma in the immunotherapy group compared with 24/53 (45%) of the untreated control group[45]. The authors concluded that immunotherapy for 3 years with grass and/or birch allergen extracts provides long-term preventive effect on the development of asthma in children with only seasonal rhinoconjunctivitis.

A similar preventive effect was also shown with SLIT in a 3-year open study of 113 children (aged 5–14 years) having grass pollen rhinitis[46]. This study demonstrated that asthma development was 3.8times more frequent in the control subjects.

There is another study which show no significant difference in symptom and medication scores in the subsequent three pollen seasons after 3-4 years of grass-pollen SCIT[47].

Marogna *et al*[48] have noted that clinical benefit persists for 8 years after SLIT treatment is given for a 4- to 5-year duration; new sensitizations were also reduced in SLIT group.

It has been documented that SCIT with a single allergen has a preventive effect against sensitization to different inhalant allergens[49-52].There are some studies which reportedsignificantly lower rate of the development of new allergen sensitizations in monosensitized patients who received SCIT in comparison to the controls[49-52].In these studies, the percentage of the development of new sensitizations were 23 %, 24 %, 24.7% and 54% in patients treated with SCIT while 68 %, 67 %, 53.3% and 100% in untreated monosensitized patients.

Recent studies have shown such effects with SLIT[48,53-55]. In a 3-year open study, 5.9 % of 511 patients with allergic rhinitis andasthma treated with SLIT showed new allergen sensitizations, while this rate was 38% in the control patients[55].

**CONCLUSİON**

SIT is the only therapeutic approach which capable to modify the natural evolution of allergic respiratory diseases. However, there are some shortcomings in trials conducted in patients with allergic asthma. In most of these studies, efficacy of SIT was not evaluated specifically in allergic asthma alone. Additionally, many of these trials had significant limitations such as low number of patients, difference in treatment protocols and doses, inadequate evaluation of pulmonary functions or absence of a placebo group. Moreover, there is a great heterogenity between studies included in meta-analyses; the most important point in this respect is the assessment of results of SIT with different allergens in the same meta-analysis.

Despite these shortcomings, the clinical efficacy of SIT has been established in allergic asthma inobjective and subjective parameters such as titrated skin tests, allergen-specific bronchial hyperreactivity, and symptom and medications scores.

Steroid sparing effect of SIT gives an important advantage for patients who have to use these drugs in high doses in order to control their asthma symptoms for many years.

SIT should be considered in asthmatic patients who experience side effects of medications, to reduce or avoid long-term pharmacotherapy and the economic burden of medications and in the presence of allergic rhinitis and/or other comorbid allergicconditions[41].

Official documents recommend that SIT should not be started in patients with unstabile asthma; in these cases, SIT can be initiated after well asthma control with appropriate pharmacotherapy.

Although both SCIT and SLIT have been reported to be effective on allergic asthma, the results of some studies or meta-analyses suggested that the efficacy of SCIT may be better and start earlier than SLIT.

Further studies are needed to discover patients who will benefit more from immunotherapy, novel vaccines and new routes of administration to increase efficacy and safety.

**REFERENCES**

1 **Bateman ED**, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, Gibson P, Ohta K, O'Byrne P, Pedersen SE, Pizzichini E, Sullivan SD, Wenzel SE, Zar HJ. Global strategy for asthma management and prevention: GINA executive summary. *Eur Respir J* 2008; **31**: 143-178 [PMID: 18166595 DOI: 10.1183/09031936.00138707]

2 **Blackwell DL**, Lucas JW, Clarke TC. Summary health statistics for U.S. adults: national health interview survey, 2012. *Vital Health Stat 10* 2014; : 1-161 [PMID: 24819891]

3 **Agache I**, Akdis C, Jutel M, Virchow JC. Untangling asthma phenotypes and endotypes. *Allergy* 2012; **67**: 835-846 [PMID: 22594878 DOI: 10.1111/j.1398-9995.2012.02832.x]

4 **Jutel M**, Akdis CA. T-cell subset regulation in atopy. *Curr Allergy Asthma Rep* 2011; **11**: 139-145 [PMID: 21271314 DOI: 10.1007/s11882-011-0178-7]

5 **Akdis CA**, Akdis M. Mechanisms of allergen-specific immunotherapy. *J Allergy Clin Immunol* 2011; **127**: 18-27; quiz 28-9 [PMID: 21211639 DOI: 10.1016/j.jaci.2010.11.030]

6 **Akdis CA**. Therapies for allergic inflammation: refining strategies to induce tolerance. *Nat Med* 2012; **18**: 736-749 [PMID: 22561837 DOI: 10.1038/nm.2754]

7 **Möller C**, Dreborg S, Ferdousi HA, Halken S, Høst A, Jacobsen L, Koivikko A, Koller DY, Niggemann B, Norberg LA, Urbanek R, Valovirta E, Wahn U. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). *J Allergy Clin Immunol* 2002; **109**: 251-256 [PMID: 11842293 DOI: 10.1067/mai.2002.121317]

8 **Calderon MA**, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. *Cochrane Database Syst Rev* 2007; **(1):** CD001936 [PMID: 17253469]

9 **Radulovic S**, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. *Cochrane Database Syst Rev* 2010; **(12):** CD002893 [PMID: 21154351]

10 **Compalati E**, Passalacqua G, Bonini M, Canonica GW. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. *Allergy* 2009; **64**: 1570-1579 [PMID: 19796205 DOI: 10.1111/j.1398-9995.2009.02129]

11 **Burks AW**, Calderon MA, Casale T, Cox L, Demoly P, Jutel M, Nelson H, Akdis CA. Update on allergy immunotherapy: American Academy of Allergy, Asthma & amp; Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. *J Allergy Clin Immunol* 2013; **131**: 1288-96.e3 [PMID: 23498595 DOI: 10.1016/j.jaci.2013.01.049]

12 **Abramson MJ**, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. *Am J Respir Crit Care Med* 1995; **151**: 969-974 [PMID: 7697274 DOI: 10.1164/ajrccm/151.4.969]

13 **Ross RN**, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of asthma: a meta-analysis of prospective, randomized, double-blind, placebo-controlled studies. *Clin Ther* 2000; **22**: 329-341 [PMID: 10963287 DOI: 10.1016/S0149-2918(00)80037-5]

14 **Basomba A**, Tabar AI, de Rojas DH, García BE, Alamar R, Olaguíbel JM, del Prado JM, Martín S, Rico P. Allergen vaccination with a liposome-encapsulated extract of Dermatophagoides pteronyssinus: a randomized, double-blind, placebo-controlled trial in asthmatic patients. *J Allergy Clin Immunol* 2002; **109**: 943-948 [PMID: 12063522 DOI: 10.1067/mai.2002.124465]

15 **Pifferi M**, Baldini G, Marrazzini G, Baldini M, Ragazzo V, Pietrobelli A, Boner AL. Benefits of immunotherapy with a standardized Dermatophagoides pteronyssinus extract in asthmatic children: a three-year prospective study. *Allergy* 2002; **57**: 785-790 [PMID: 12169173 DOI: 10.1034/j.1398-9995.2002.23498]

16 **García-Robaina JC**, Sánchez I, de la Torre F, Fernández-Caldas E, Casanovas M. Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study. *J Allergy Clin Immunol* 2006; **118**: 1026-1032 [PMID: 17088125 DOI: 10.1016/j.jaci.2006.07.043]

17 **Roberts G**, Hurley C, Turcanu V, Lack G. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. *J Allergy Clin Immunol* 2006; **117**: 263-268 [PMID: 16461125 DOI: 10.1016/j.jaci.2005.09.054]

18 **Zielen S**, Kardos P, Madonini E. Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial. *J Allergy Clin Immunol* 2010; **126**: 942-949 [PMID: 20624650 DOI: 10.1016/j.jaci.2010.06.002.]

19 **Abramson MJ**, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. *Cochrane Database Syst Rev* 2010; **(8):** CD001186 [PMID: 20687065 DOI: 10.1002/14651858.CD001186.pub2]

20 **Blumberga G**, Groes L, Haugaard L, Dahl R. Steroid-sparing effect of subcutaneous SQ-standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics. *Allergy* 2006; **61**: 843-848 [PMID: 16792582 DOI: 10.1111/j.1398-9995.2006.01088]

21 **Maestrelli P**, Zanolla L, Pozzan M, Fabbri LM; Regione Veneto Study Group on the “Effect of immunotherapy in allergic asthma”. Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite. *J Allergy Clin Immunol* 2004; **113** (4): 643 – 649 [PMID: 15100667 DOI: 10.1016/j.jaci.2003.12.586]

22 **Adkinson NF**, Eggleston PA, Eney D, Goldstein EO, Schuberth KC, Bacon JR, Hamilton RG, Weiss ME, Arshad H, Meinert CL, Tonascia J, Wheeler B. A controlled trial of immunotherapy for asthma in allergic children. *N Engl J Med* 1997; **336**: 324-331 [PMID: 9011784 DOI: 10.1056/NEJM199701303360502]

23 **Canonica GW**, Bousquet J, Casale T, Lockey RF, Baena-Cagnani CE, Pawankar R, Potter PC, Bousquet PJ, Cox LS, Durham SR, Nelson HS, Passalacqua G, Ryan DP, Brozek JL, Compalati E, Dahl R, Delgado L, van Wijk RG, Gower RG, Ledford DK, Filho NR, Valovirta EJ, Yusuf OM, Zuberbier T, Akhanda W, Almarales RC, Ansotegui I, Bonifazi F, Ceuppens J, Chivato T, Dimova D, Dumitrascu D, Fontana L, Katelaris CH, Kaulsay R, Kuna P, Larenas-Linnemann D, Manoussakis M, Nekam K, Nunes C, O'Hehir R, Olaguibel JM, Onder NB, Park JW, Priftanji A, Puy R, Sarmiento L, Scadding G, Schmid-Grendelmeier P, Seberova E, Sepiashvili R, Solé D, Togias A, Tomino C, Toskala E, Van Beever H, Vieths S. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. *Allergy* 2009; **64** Suppl 91: 1-59 [PMID: 20041860 DOI: 10.1097/WOX.0b013e3181c6c379]

24 **Olaguíbel JM**, Alvarez Puebla MJ. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. *J Investig Allergol Clin Immunol* 2005; **15**: 9-16 [PMID: 15864877]

25 **Calamita Z**, Saconato H, Pelá AB, Atallah AN. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. *Allergy* 2006; **61**: 1162-1172 [PMID: 16942563 DOI: 10.1111/j.1398-9995.2006.01205]

26 **Penagos M**, Passalacqua G, Compalati E, Baena-Cagnani CE, Orozco S, Pedroza A, Canonica GW. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. *Chest* 2008; **133**: 599-609 [PMID: 17951626 DOI: 10.1097/01.WOX.0000301999.54398.13]

27 **Mosbech H**. Tolerability and efficacy of house dust mite AIT. *Allergy* 2011; **66** Suppl 95: 55-56 [PMID: 21668857 DOI: 10.1111/j.1398-9995.2011.02641]

28 **Marogna M**, Braidi C, Bruno ME, Colombo C, Colombo F, Massolo A, Palumbo L, Compalati E. The contribution of sublingual immunotherapy to the achievement of control in birch-related mild persistent asthma: a real-life randomised trial. *Allergol Immunopathol (Madr)* 2013; **41**: 216-224 [PMID: 23141837 DOI: 10.1016/j.aller.2012.07.004]

29 **Mungan D**, Misirligil Z, Gürbüz L. Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma--a placebo controlled study. *Ann Allergy Asthma Immunol* 1999; **82**: 485-490 [PMID: 10353581 DOI: 10.1016/S1081-1206(10)62726-3]

30 **Eifan AO**, Akkoc T, Yildiz A, Keles S, Ozdemir C, Bahceciler NN, Barlan IB. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial. *Clin Exp Allergy* 2010; **40**: 922-932 [PMID: 20100188 DOI: 10.1111/j.1365-2222.2009.03448]

31 **Keles S**, Karakoc-Aydiner E, Ozen A, Izgi AG, Tevetoglu A, Akkoc T, Bahceciler NN, Barlan I. A novel approach in allergen-specific immunotherapy: combination of sublingual and subcutaneous routes. *J Allergy Clin Immunol* 2011; **128**: 808-815.e7 [PMID: 21641635 DOI: 10.1016/j.jaci.2011.04.033]

32 **Yukselen A**, Kendirli SG, Yilmaz M, Altintas DU, Karakoc GB. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study. *Int Arch Allergy Immunol* 2012; **157**: 288-298 [PMID: 22041501 DOI: 10.1159/000327566]

33 **Yukselen A**, Kendirli SG, Yilmaz M, Altintas DU, Karakoc GB. Two year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing subcutaneous and sublingual immunotherapy. *Asian Pac J Allergy Immunol* 2013; **31**: 233-241 [PMID: 24053706 DOI: 10.12932/AP0276.31.3.2013]

34 **Chelladurai Y**, Suarez-Cuervo C, Erekosima N, Kim JM, Ramanathan M, Segal JB, Lin SY. Effectiveness of subcutaneous versus sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. *J Allergy Clin Immunol Pract* 2013; **1**: 361-369 [PMID: 24565541 DOI: 10.1016/j.jaip.2013.04.005]

35 **Passalacqua G**, Durham SR; Global Allergy and Asthma European Network. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. *J Allergy Clin Immunol* 2007; **119**: 881-891 [PMID: 17418661 DOI: 10.1016/j.jaci.2007.01.045]

36 **Corrigan CJ**, Kettner J, Doemer C, Cromwell O, Narkus A. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. *Allergy* 2005; **60**: 801-807 [PMID: 15876311 DOI: 10.1111/j.1398-9995.2005.00790]

37 **Jutel M**, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. *J Allergy Clin Immunol* 2005; **116**: 608-613 [PMID: 16159631 DOI: 10.1016/j.jaci. 2005.06.004]

38 **Bernstein DI**, Epstein T, Murphy-Berendts K, Liss GM. Surveillance of systemic reactions to subcutaneous immunotherapy injections: year 1 outcomes of the ACAAI and AAAAI collaborative study. *Ann Allergy Asthma Immunol* 2010; **104**: 530-535 [PMID: 20568387 DOI: 10.1016/j.anai.2010.04.008]

39 **Schiappoli M**, Ridolo E, Senna G, Alesina R, Antonicelli L, Asero R, Costantino MT, Longo R, Musarra A, Nettis E, Crivellaro M, Savi E, Massolo A, Passalacqua G. A prospective Italian survey on the safety of subcutaneous immunotherapy for respiratory allergy. *Clin Exp Allergy* 2009; **39**: 1569-1574 [PMID: 19486027 DOI: 10.1111/j.1365-2222.2009.03286.x]

40 **Rank MA**, Oslie CL, Krogman JL, Park MA, Li JT. Allergen immunotherapy safety: characterizing systemic reactions and identifying risk factors. *Allergy Asthma Proc* ; **29**: 400-405 [PMID: 18702889 DOI: 10.2500/aap.2008.29.3141]

41 **Cox L,** Li JT, Nelson H, Lockey R. Allergen immunotherapy: a practice parameter second update. *J Allergy Clin Immunol* 2007; **120**: S25-S85 [PMID: 17765078 DOI: 10.1016/j.jaci.2007.06.019]

42 **Dahl R**, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. *Allergy* 2006; **61**: 185-190 [PMID: 16409194 DOI: 10.1111/j.1398-9995.2005.00949.x]

43 **Alvarez-Cuesta E**, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta E; EAACI Immunotherapy Task Force. Standards for practical allergen-specific immunotherapy. *Allergy* 2006; **61** Suppl 82: 1-20 [PMID: 16930249 DOI: 10.1111/j.1398-9995.2006.01219]

44 **Burastero S**. Regarding Gidaro GB, Marcucci F, Sensi L, Incorvaia C, Frati F, Ciprandi G. The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin Exp Allergy 2005; 35: 565-71. *Clin Exp Allergy* 2005; **35**: 1407-148; author reply 1409 [PMID: 16238803 DOI: 10.1111/j.1365-2222.2005.02366]

45 **Jacobsen L**, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Høst A, Koivikko A, Norberg LA, Valovirta E, Wahn U, Möller C; The PAT investigator group. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. *Allergy* 2007; **62**: 943-948 [PMID: 17620073 DOI: 10.1111/j.1398-9995.2007.01451.x]

46 **Novembre E**, Galli E, Landi F, Caffarelli C, Pifferi M, De Marco E, Burastero SE, Calori G, Benetti L, Bonazza P, Puccinelli P, Parmiani S, Bernardini R, Vierucci A. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. *J Allergy Clin Immunol* 2004; **114**: 851-857 [PMID: 15480326 DOI: 10.1016/j.jaci.2004.07.012]

47 **Durham SR**, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, Till SJ, Hamid QA, Nouri-Aria KT. Long-term clinical efficacy of grass-pollen immunotherapy. *N Engl J Med* 1999; **341**: 468-475 [PMID: 10441602 DOI: 10.1056/NEJM199908123410702]

48 **Marogna M**, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. *J Allergy Clin Immunol* 2010; **126**: 969-975 [PMID: 20934206 DOI: 10.1016/j.jaci.2010.08.030]

49 **Des Roches A**, Paradis L, Menardo JL, Bouges S, Daurés JP, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. *J Allergy Clin Immunol* 1997; **99**: 450-453 [PMID: 9111487 DOI: 10.1016/S0091-6749(97)70069-1]

50 **Pajno GB**, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. *Clin Exp Allergy* 2001; **31**: 1392-1397 [PMID: 11591189 DOI: 10.1046/j.1365-2222.2001.01161]

51 **Purello-D'Ambrosio F**, Gangemi S, Merendino RA, Isola S, Puccinelli P, Parmiani S, Ricciardi L. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. *Clin Exp Allergy* 2001; **31**: 1295-1302 [PMID: 11529901 DOI: 10.1046/j.1365-2222.2001.01027]

52 **Inal A**, Altintas DU, Yilmaz M, Karakoc GB, Kendirli SG, Sertdemir Y. Prevention of new sensitizations by specific immunotherapy in children with rhinitis and/or asthma monosensitized to house dust mite. *J Investig Allergol Clin Immunol* 2007; **17**: 85-91 [PMID: 17460946]

53 **Marogna M**, Tomassetti D, Bernasconi A, Colombo F, Massolo A, Businco AD, Canonica GW, Passalacqua G, Tripodi S. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. *Ann Allergy Asthma Immunol* 2008; **101**: 206-211 [PMID: 18727478 DOI: 10.1016/S1081-1206(10)60211-6]

54 **Durham SR**, Emminger W, Kapp A, Colombo G, de Monchy JG, Rak S, Scadding GK, Andersen JS, Riis B, Dahl R. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. *J Allergy Clin Immunol* 2010; **125**: 131-8.e1-131-8.e7 [PMID: 20109743 DOI: 10.1016/j.jaci.2009.10.035]

**P-Reviewer:** Hattori N, Lee, SH **S-Editor:** Tian YL

**L-Editor: E-Editor:**

**Table 1 Head-to-head studies which included patients with asthma treated by subcutaneous and sublingual immunotherapy1**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Year** | **Study Design** | **Age** | **No of patients** | **Asthma symptom score** | | | | **Medication score** | | | | **Findings** |
| **Before SIT** | | **After SIT** | | **Before SIT** | | **After SIT** | |
| **SSCIT** | **SSLIT** | **LSCIT** | **SSLIT** | **LSCIT** | **SLIT** | **SCIT** | **SSLIT** |
| Mungan *et al*[29] | 1999 | Single-blind, placebo controlled | Adults | SCIT (*n* = 10)  SLIT (*n* =15)  Placebo (*n* = 11) | 1.20 | 0.63 | 0.59 | 0.41 | 6.8 | 4.93 | 3.9 | 1.97 | Reduction in symptom scores  with only SCIT  Reduction in medication  scores with both  SCIT and SLIT |
| Eifan *et al*[30] | 2010 | Open label, randomized,  controlled | 5-10 | SCIT (*n* = 16)  SLIT (*n* = 16)  Pharmacotherapy (*n* = 16) | 0.9 ± 0.7 | 1.4 ± 1.5 | 0.4 ± 0.6 | 0.2 ± 0.4 | 2.4 ± 1.4 | 2.8 ± 1.2 | 1.7 ± 1.4 | 1.2 ± 0.9 | Reducttion in symptom and  medication scores and  visual analog scores with  both SCIT and SLIT |
| Keles *et al*[31] | 2011 | Open label, randomized, controlled | 5-12 | SCIT (*n* = 11)  SLIT (*n* = 13)  SCIT plus SLIT (*n* = 14)  Pharmacotherapy (*n* = 12) | 0.25 | 0.12 | 0 | 0 | 0.52 | 0.69 | 0.06 | 0.23 | Reduction in symptom scores  and visual analog scores  with both SCIT and SLIT |
| Yukselen *et al*[32] | 2012 | Randomized, double-blind,  double-dummy,  placebo-controlled | 6-14 | SCIT (*n* = 10)  SLIT (*n* = 11)  Placebo (*n* =10 ) | 2.4 | 3.7 | 1 | 2.7 | 2.3 | 2.3 | 1.0 | 1.7 | Only SCIT was found  superior to placebo on  reduction of  symptom and medication  scores. |

1All studies used HDM immunotherapy. SCIT : Subcutaneous immunotherapy; SLIT: Sublingual immunotherapy.